Extented measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003-2004

Eurosurveillance

Volumn 15, Issue 46, 2010, Pages

  Kassis Chikhani, N ^a   Saliba, F ^a   Carbonne, A ^b   Neuville, S ^c   Decre, D ^d,e   Sengelin, C ^a   Guerin, C ^a   Gastiaburu, N ^a   Lavigne Kriaa, A ^a   Boutelier, C ^a   Arlet, G ^e,f   Samuel, D ^a,g   Castaing, D ^a,g   Dussaix, E ^a,g   Jarlier, V ^c,e,h  

^a HÔPITAL PAUL BROUSSE   (France)

^b Centre de Coordination de la Lutte contre les Infections Nosocomiales   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f HÔPITAL TENON   (France)

^g Universite Paris Sud   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE VIM 1; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; VIM 1 METALLO BETA LACTAMASE; VIM-1 METALLO-BETA-LACTAMASE;

ACUTE LIVER FAILURE; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM CARRIER; CLINICAL ARTICLE; ENZYME SYNTHESIS; EPIDEMIC; FRANCE; GREECE; HAND WASHING; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE INFECTION; LIVER ABSCESS; LIVER TRANSPLANTATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT TRANSPORT; SCREENING TEST; SURGICAL WARD; CLASSIFICATION; CROSS INFECTION; ENZYMOLOGY; FEMALE; HOSPITAL BED CAPACITY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; FEMALE; FRANCE; HOSPITAL BED CAPACITY, 500 AND OVER; HUMANS; IMIPENEM; INFECTION CONTROL; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIVER TRANSPLANTATION; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 78649456733     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R et al. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43(7): 1584-90.
2. Jeong SH, Lee K, Chong Y, Yum JH, Lee SH, Choi HJ, et al. Characterization of a new integron containing VIM-2, a metallo-β-lactamase gene cassette, in a clinical isolate of Enterobacter cloacae. J Antimicrob Chemother. 2003;51(2):397-400.
3. Scoulica EV, Neonakis IK, Gikas AI, Tselentis YJ et al. Spread of blaVIM-producing E. coli in a university hospital in Greece. Genetic analysis of the integron carrying the blaVIM-1 metallo-β-lactamase gene. Diag Microbiol Infect Dis. 2004;48:167-72.
4. Conceicao T, Brizio A, Duarte A, Barros R, et al. First isolation of bla(VIM-2) in Klebsiella oxytoca clinical isolates from Portugal. Antimicrob Agents Chemother. 2005;49(1): 476.
5. Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo-beta-lactamaseproducing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J Antimicrob Agents Chemother. 2002;50(4): 503-11.
6. Yum HY, Yong D, Kim HS, Chong Y. A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens. Diagn Microbiol Infect Dis. 2002;42(3): 217-8.
7. Miriagou V, Tzelepi E, Gianneli D, Tzouvelekis LS. Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-beta-lactamase VIM-1. Antimicrob Agent Chemother. 2003;47(1): 395-7.
8. Giakkoupi P, Xanthaki A, Kanelopoulou M, Vlahaki A, Miriagou V, Kontou S et al. VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol. 2003; 41(8): 3893-6.
9. Galani I, Souli M, Chryssouli Z et al. First identification of an Escherichia coli clinical isolate producing both metallo-betalactamase VIM-2 and extended-spectrum β-lactamase IBC-1. Clin Microbiol Infect. 2004;10(8): 757-60.
10. Luzzaro F, Docquier JD, Colinon C et al. Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-beta-lactamase encoded by a conjugative plasmid. Antimicrob Agent Chemother. 2004;48(2): 648-50.
11. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol. 2000;38(3):1290-2.
12. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clin Infect Dis. 2000;31(5):1119-25
13. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9(4):228-36. Review.
14. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009; 53(12):5046-54.
15. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10 (9):597-602.
16. MacPherson DW, Gushulak BD, Baine WB, Bala S, Gubbins PO, Holtom P et al. Population mobility, globalization, and antimicrobial drug resistance. Emerg Infect Dis. 2009;15(11):1727-32.
17. Kassis-Chikhani N, Decré D, Gautier V Burghoffer B, Saliba F, Mathieu D et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother. 2006;57(1):142-5.
18. Comité Technique national des Infections Nosocomiales (CTIN): Maîtrise de la diffusion des bactéries multirésistantes aux antibiotiques. Recommandations pour les établissements de santé. Ministère de l'Emploi et de la Solidarité, Secrétariat d'Etat à la Santé et à l'Action sociale. 1999.
19. Comité de l'antibiogramme de la Société Française de Microbiologie (SFM). Recommandations 2010; page 4. Available from: http://www.sfm.asso.fr/publi/general.php?pa=1
20. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report on communicable diseases in Europe 2008. Report on the state of communicable diseases in the EU and EEA/EFTA countries, p 173. Stockholm; 2008. Available from: http://ecdc.europa.eu/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf.
21. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC and Perencevich EN. The use and interpretation of quasiexperimental studies in infectious diseases. Clin Infect Dis. 2004;38(11):1586-91
22. Vatopoulos A. High rates of metallo-beta-lactamaseproducing Klebsiella pneumoniae in Greece -a review of the current evidence. Euro Surveill. 2008;13(4):pii=8023. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8023
23. Cagnacci S, Gualco L, Roveta S Mannelli S, Borgianni L, Docquier JD et al. Bloodstream infections caused by multidrugresistant Klebsiella pneumoniae producing the carbapenemhydrolysing VIM-1 metallo-beta-lactamase: first Italian outbreak. J Antimicrob Chemother. 2008;61(2):296-300
24. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City. Arch Intern Med. 2005;165(12):1430-35.
25. Kochar S, Sheard T, Sharma R, Hui A, Tolentino E, Allen G et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009;30(5):447-52.
26. Lucet JC, Armand-Lefevre L, Laurichesse JJ, Macrez A, Papy E, Ruimy R et al. Rapid control of an outbreak of vancomycinresistant enterococci in a French university hospital. J.Hosp Infect. 2007; 67(1):42-8.
27. Ridwan B, Mascini E, van Der Reijden N, Verhoef J and Bonten M. What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals? BMJ. 2002;324(7338):666-8
28. Kurup A, Chlebicki MP, Ling ML, Koh, TH, Tan KY, Lee LC, et al. Control of a hospital-wide vancomycin-resistant Enterococci outbreak. Am J Infect Control. 2008;36(3):206-11
29. Prévention de l'émergence des épidémies d'entérocoques résistants à la vancomycine dans les établissements de santé. Fiche technique opérationnelle. Décembre 2006.
30. Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. Morb Mortal Wkly Rep. 2009 Mar 20;58(10):256-60.
31. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect. 2010;16(2):102-11.
32. Schwaber MJ, Carmeli Y. Carbapenem-resistant-Enterobacteriaceae: A potential threat. JAMA. 2008;300(24):2911-3